Rigel Pharma Live Stock Price Today, Share Analysis and Chart

Name: Rigel Pharmaceuticals: Is Infosys Ltd. worth buying?
Item: Rigel Pharmaceuticals
Rating: 2.040333375
Author: Trendlyne DVM scores

Turnaround Potential

about

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsi...

41.66 1.49 (3.71%)

66.97% Gain from 52W Low

230.3K

XNAS Volume

XNAS 10 Aug, 2026 5:30 PM (EDT)

Low Financial Strength

16.7 / 100

Affordable Valuation

64.3 / 100

Technically Moderately Bullish

65.6 / 100

Turnaround Potential These stocks have weak financials, buying interest and affordable valuations. Investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 33%

5 analysts

Rigel Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Rigel Pharma Live Stock Price Today, Share Analysis and Chart

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsi...

66.97% Gain from 52W Low

SWOT Analysis

Rigel Pharma Live Price Chart

Rigel Pharma Live Price Chart